MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer
Source abstract
Abstract
Triple-negative breast cancer (TNBC) is a distinct subtype of breast cancer characterized by high recurrence rates and poor prognosis compared to other breast cancers. MicroRNAs (miRNAs) are small non-coding RNAs that regulate the expression of various post-transcriptional gene and silence a broad set of target genes. Many recent studies have demonstrated that miRNAs play an important role in the initiation, promotion, malignant conversion, progression, and metastasis of TNBC. Therefore, the aim of this review is to focus on recent advancements of microRNAs-based potential applications in diagnosis, treatment and prognosis of triple-negative breast cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: MicroRNA in disease regulation · Circular RNAs in diseases · Cancer-related molecular mechanisms research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Pharmacy and Pharmacology, University of South China
Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study
Funding
Innovation platform Open Foundation of education department of Hunan province · University of South China Innovation Foundation For Postgraduate
References (100+)
Show source-provided references
1. 10.1016/S0140-6736(16)31012-110.1016/S0140-6736(16)31012-1 ↗
2. 10.3322/caac.2120310.3322/caac.21203 ↗
3. 10.18632/oncotarget.441910.18632/oncotarget.4419 ↗
4. 10.1016/j.ctrv.2017.10.01410.1016/j.ctrv.2017.10.014 ↗
5. 10.1172/JCI4501410.1172/JCI45014 ↗
6. 10.1016/j.ejca.2008.09.03410.1016/j.ejca.2008.09.034 ↗
7. 10.1186/s13058-015-0588-x10.1186/s13058-015-0588-x ↗
8. 10.1007/s10549-010-1293-110.1007/s10549-010-1293-1 ↗
9. 10.1016/j.bbacli.2015.03.00310.1016/j.bbacli.2015.03.003 ↗
10. 10.1007/s10354-010-0773-610.1007/s10354-010-0773-6 ↗
11. 10.1038/nature1093310.1038/nature10933 ↗
12. 10.1101/gad.248377.11410.1101/gad.248377.114 ↗
13. 10.1007/s13277-014-3009-310.1007/s13277-014-3009-3 ↗
14. 10.1007/s13277-015-4605-610.1007/s13277-015-4605-6 ↗
15. 10.1016/j.biopha.2017.09.10710.1016/j.biopha.2017.09.107 ↗
16. 10.1158/1078-0432.CCR-14-201110.1158/1078-0432.CCR-14-2011 ↗
17. 10.3390/ijms14112220210.3390/ijms141122202 ↗
18. 10.1371/journal.pone.005591010.1371/journal.pone.0055910 ↗
19. 10.4161/cc.2475710.4161/cc.24757 ↗
20. 10.1172/JCI6494610.1172/JCI64946 ↗
21. 10.1038/onc.2015.18910.1038/onc.2015.189 ↗
22. 10.1007/s13277-013-0708-010.1007/s13277-013-0708-0 ↗
23. 10.4161/cc.10.3.1475410.4161/cc.10.3.14754 ↗
24. 10.18632/oncotarget.252010.18632/oncotarget.2520 ↗
25. 10.1007/s12253-017-0188-410.1007/s12253-017-0188-4 ↗
26. 10.1371/journal.pone.008703910.1371/journal.pone.0087039 ↗
27. 10.1002/emmm.20110013610.1002/emmm.201100136 ↗
28. 10.1186/bcr280310.1186/bcr2803 ↗
29. 10.1016/j.biopha.2018.04.16510.1016/j.biopha.2018.04.165 ↗
30. 10.1016/j.biopha.2017.02.02810.1016/j.biopha.2017.02.028 ↗
31. Wang C, Ju H, Shen C, et al. miR-429 mediates δ-tocotrienol-induced apoptosis in triple-negative breast cancer cells by targeting XIAP. Int J Clin Exp Med. 2015;8:15648–15656.
32. 10.1186/s12943-017-0754-010.1186/s12943-017-0754-0 ↗
33. 10.18632/oncotarget.1430710.18632/oncotarget.14307 ↗
34. 10.18632/oncotarget.168210.18632/oncotarget.1682 ↗
35. 10.1371/journal.pone.005170210.1371/journal.pone.0051702 ↗
36. 10.12659/MSM.89397410.12659/MSM.893974 ↗
37. 10.1016/j.humpath.2017.08.02610.1016/j.humpath.2017.08.026 ↗
38. 10.1038/onc.2017.23110.1038/onc.2017.231 ↗
39. 10.1074/jbc.M109.08333710.1074/jbc.M109.083337 ↗
40. 10.1093/carcin/bgs16110.1093/carcin/bgs161 ↗
41. 10.1161/CIRCRESAHA.111.24743710.1161/CIRCRESAHA.111.247437 ↗
42. 10.1038/bjc.2016.210.1038/bjc.2016.2 ↗
43. Si C, Yu Q, Yao Y. Effect of miR-146a-5p on proliferation and metastasis of triple-negative breast cancer via regulation of SOX5. Exp Ther Med. 2018;15:4515–4521.
44. 10.1016/j.canlet.2014.11.05010.1016/j.canlet.2014.11.050 ↗
45. 10.3892/or.2016.476710.3892/or.2016.4767 ↗
46. 10.18632/oncotarget.795310.18632/oncotarget.7953 ↗
47. 10.1186/1756-9966-31-5810.1186/1756-9966-31-58 ↗
48. 10.1016/j.gene.2016.08.01410.1016/j.gene.2016.08.014 ↗
49. Li D, Hu J, Song H, et al. miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells. Am J Transl Res. 2017;9:2276–2285.
50. 10.18632/oncotarget.907210.18632/oncotarget.9072 ↗
51. 10.1158/1541-7786.MCR-14-025110.1158/1541-7786.MCR-14-0251 ↗
52. 10.12659/MSM.89773110.12659/MSM.897731 ↗
53. 10.1038/cr.2009.1810.1038/cr.2009.18 ↗
54. 10.1016/j.molonc.2012.03.00310.1016/j.molonc.2012.03.003 ↗
55. 10.1016/j.canlet.2018.06.03710.1016/j.canlet.2018.06.037 ↗
56. 10.1186/s12885-017-3674-x10.1186/s12885-017-3674-x ↗
57. 10.3892/ijo.2016.376110.3892/ijo.2016.3761 ↗
58. 10.1186/s12935-018-0512-410.1186/s12935-018-0512-4 ↗
59. 10.7150/jca.1931510.7150/jca.19315 ↗
60. 10.2147/OTT.S10271310.2147/OTT.S102713 ↗
61. 10.1371/journal.pone.017639510.1371/journal.pone.0176395 ↗
62. 10.1093/carcin/bgv08710.1093/carcin/bgv087 ↗
63. 10.1093/carcin/bgu13310.1093/carcin/bgu133 ↗
64. 10.18632/oncotarget.318410.18632/oncotarget.3184 ↗
65. 10.3892/mmr.2014.222210.3892/mmr.2014.2222 ↗
66. 10.1371/journal.pone.004998710.1371/journal.pone.0049987 ↗
67. 10.1158/1541-7786.MCR-18-024610.1158/1541-7786.MCR-18-0246 ↗
68. 10.1158/0008-5472.CAN-15-232110.1158/0008-5472.CAN-15-2321 ↗
69. 10.1002/cbin.1070010.1002/cbin.10700 ↗
70. 10.1007/s10549-011-1690-010.1007/s10549-011-1690-0 ↗
71. 10.1007/s12032-014-0361-510.1007/s12032-014-0361-5 ↗
72. 10.1016/j.bbrc.2016.06.07610.1016/j.bbrc.2016.06.076 ↗
73. 10.1016/j.molonc.2014.07.00610.1016/j.molonc.2014.07.006 ↗
74. 10.1016/j.gene.2016.08.05710.1016/j.gene.2016.08.057 ↗
75. 10.1002/ijc.2579310.1002/ijc.25793 ↗
76. 10.1074/jbc.M112.41412810.1074/jbc.M112.414128 ↗
77. 10.1016/j.cellsig.2018.01.01310.1016/j.cellsig.2018.01.013 ↗
78. 10.1016/j.molcel.2010.12.00510.1016/j.molcel.2010.12.005 ↗
79. 10.1186/s13058-014-0435-510.1186/s13058-014-0435-5 ↗
80. 10.18632/oncotarget.519210.18632/oncotarget.5192 ↗
81. 10.1016/j.ajpath.2012.02.02410.1016/j.ajpath.2012.02.024 ↗
82. 10.18632/oncotarget.403910.18632/oncotarget.4039 ↗
83. 10.1371/journal.pone.006513810.1371/journal.pone.0065138 ↗
84. 10.1016/j.tranon.2018.10.00110.1016/j.tranon.2018.10.001 ↗
85. 10.1007/s40291-015-0143-610.1007/s40291-015-0143-6 ↗
86. 10.1016/j.canlet.2014.07.03610.1016/j.canlet.2014.07.036 ↗
87. 10.1158/0008-5472.CAN-11-060810.1158/0008-5472.CAN-11-0608 ↗
88. 10.1007/s13277-014-2611-810.1007/s13277-014-2611-8 ↗
89. 10.1016/j.talanta.2018.07.01610.1016/j.talanta.2018.07.016 ↗
90. 10.7314/APJCP.2012.13.3.87310.7314/APJCP.2012.13.3.873 ↗
91. 10.1007/s10549-015-3460-x10.1007/s10549-015-3460-x ↗
92. 10.1007/s12032-014-0057-x10.1007/s12032-014-0057-x ↗
93. Yang L, Feng Y, Qi P, et al. Mechanism of serum miR-21 in the pathogenesis of familial and triple negative breast cancer. J Biol Regul Homeost Agents. 2016;30:1041–1045.
94. 10.1016/j.ajpath.2014.08.02010.1016/j.ajpath.2014.08.020 ↗
95. 10.1371/journal.pone.010066410.1371/journal.pone.0100664 ↗
96. 10.1093/jjco/hys00110.1093/jjco/hys001 ↗
97. 10.18632/oncotarget.1176410.18632/oncotarget.11764 ↗
98. 10.1186/1746-1596-7-3110.1186/1746-1596-7-31 ↗
99. 10.1007/s12032-014-0283-210.1007/s12032-014-0283-2 ↗
100. 10.3349/ymj.2017.58.4.69710.3349/ymj.2017.58.4.697 ↗